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Medicinal mushrooms have been used for centuries as nutraceuticals to improve health and to treat
numerous chronic and infectious diseases. One such mushroom is Ganoderma lucidum, commonly known
as Lingzhi, a species revered as a medicinal mushroom for treating assorted diseases and prolonging life.
The fungus is found in diverse locations, and this may have contributed to confusion regarding the correct
taxonomic classiﬁcation of the genus Ganoderma. G. lucidum was ﬁrst used to name a specimen found in
England and thereafter was naively applied to a different Ganoderma species found in Asia, commonly
known as Chinese Lingzhi. Despite the taxonomic confusion, which has largely been uncorrected, the
popularity of Lingzhi has escalated across the globe. The current taxonomic situation is now discussed
accurately in this Special Issue on Ganoderma. Today it is a multi-billion dollar industry wherein
Lingzhi is cultivated or collected from the wild and consumed as a tea, in alcoholic beverages, and as a
nutraceutical to confer numerous health beneﬁts. Consumption of nutraceuticals has grown in
popularity, and it is becoming increasingly important that active ingredients be identiﬁed and that
suppliers make substantiated health claims about their products. The objective of this article is to present
a review of G. lucidum over the past 2000 years from prized ancient ‘‘herbal’’ remedy to its use in
nutraceuticals and to the establishment of a 2.5 billion $ (US) industry.
 2015 Elsevier Ltd. All rights reserved.1. Introduction to medicinal mushrooms as nutraceuticals the term ‘‘nutraceutical’’ is not globally accepted and has no reg-The word ‘‘nutraceutical’’ was ﬁrst coined by Stephen Defelice
when he combined the terms ‘‘nutrition’’ and ‘‘pharmaceutical’’
in 1989 (Brower, 1998). From that point on there has been much
controversy regarding whether nutraceuticals should be consid-
ered as foods or medicines, and whether they should be regulated.
One particular deﬁnition describes a nutraceutical as a product
that is isolated from a food, and believed to have a beneﬁt to health
or prevention of chronic disease (Health Canada, 1998). However,ulatory deﬁnition (Gautam, 2013). Broadly speaking, nutraceuti-
cals encompass functional foods, the active components of
functional foods, dietary supplements and medicinal foods
(Brower, 1998) as well as foods containing probiotics (Chaturvedi
et al., 2011), and this is how the term is interpreted from the point
of view of this article. The following deﬁnition will be understood
for probiotics: ‘‘live microorganisms that, when administered in
adequate amounts, confer a health beneﬁt on the host’’ (FAO/
WHO, 2002).
Numerous mushrooms have for centuries been revered for their
miracle cures and general health promoting beneﬁts (Ferreira et al.,
2010). Predominantly in Asian countries, various mushroom
species are grown in the wild and used as nutraceuticals, despite
much of the evidence for beneﬁt being anecdotal or obtained from
animal model experiments. Nonetheless, there is evidence of
potential beneﬁt from using various mushroom extracts with
respect to anti-bacterial, anti-inﬂammatory, anti-viral, anti-
atherosclerotic, anti-diabetic and anti-cancer activity (De Silva
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widely used drugs were obtained from plant sources, and in order
to promote wide use of these drugs in modern times, the key active
ingredients were identiﬁed and synthesised. An example of a drug
that is widely used for its medicinal properties and whose design
was based on medicinal properties of an active ingredient from a
plant source is Aspirin. Aspirin is the trade name for acetylsalicylic
acid, a prodrug, which was inspired by anecdotal evidence of the
medicinal properties of salicylic acid. Salicylic acid is the active
ingredient originally obtained from salicylate rich plants such as
willow (Raskin, 1992) and used for centuries before the mecha-
nism of action was identiﬁed. Many feel that medicinal mush-
rooms are underutilised and have huge potential for providing
health beneﬁt (Jenkin, 2014). However, some regard the active
ingredients of mushrooms too complex to synthesise (as claimed
by Chris Kilham in (Jenkin, 2014)) or is it that we have not delved
sufﬁciently deeply into the treasure chest of nutraceutical-fungal
biochemistry? Regardless of whether evidence is anecdotal or
clinically proven, nutraceuticals are ﬂooding onto the market.
However, with growing competition and awareness, consumers
are becoming increasingly discerning and seeking proof for claims
made, thus making it necessary to identify the active ingredients in
order to report on the quantity present in the nutraceutical being
purchased. In addition, scientiﬁc evidence is often essential to
appease mounting regulatory requirements when making health
claims with respect to nutraceuticals (Chaturvedi et al., 2011).
For these reasons, amongst others, it is important to support health
claims made about a nutraceutical product with scientiﬁc
evidence, rather than making loose statements regarding the
superiority of one Ganoderma lucidum based product over another.
There are a number of fungal species that are traditionally used
as nutraceuticals around the globe (Ajith and Janardhanan, 2007;
Ferreira et al., 2010; Wasser, 2011). These include G. lucidum
(Lingzhi), Ophiocordyceps (previously Cordyceps) species
(Paterson, 2008), Grifola frondosa (Hen of the woods/Maitake),
Lentinula edodes (Shiitake), Piptoporus betulinus (Birch polypore/
bracket), Inonotus obliquus (Chaga), and Agaricus subrufescens
(Almond mushroom), amongst numerous others (De Silva et al.,
2012; Wasser, 2011). However, Lingzhi is probably the most
widely known and highly revered medicinal mushroom amongst
populations living in Asia.
2. Historical usage of G. lucidum: the ‘‘Mushroom of
Immortality’’
The objective of this article is to present a review of G. lucidum
over the past 2000 years from prized ancient ‘‘herbal’’ remedy to
its use in nutraceuticals and to the establishment of a 2.5 billion
$ (US) industry (Li et al., 2013). Worldwide, the species name G.
lucidum has been applied to Chinese Lingzhi (Wang et al., 2012b)
which is well known as a basidiomycete and has been referred to
as the ‘‘Mushroom of Immortality’’ (Li et al., 2013). Lingzhi has
been widely used in China for medicinal purposes since before
the common era (BCE). This fungus has been predominantly used
by Asian populations to not only improve wellbeing and general
health (Shiao, 2003), but has also been used alone or alongside
Western chemotherapy treatment to inhibit cancer or to assist
with side-effects (Gordan et al., 2011; Papadopoulos et al., 2007;
Sliva, 2003). In addition, its use has become increasingly wide-
spread to prevent obesity; reduce cholesterol; for the maintenance
of gut health; reduction of hypertension; control of diabetes and
the stimulation of probiotics, amongst others (Jin et al., 2012;
Paterson, 2006; Sanodiya et al., 2009).
In ancient times, Lingzhi was grown in the wild and consumed
only by the very wealthy, whereas nowadays a large proportion is
cultivated and is more widely consumed across socioeconomicgroups as an alternative to, or alongside, modern medicine
(Leung et al., 2003; Zhao et al., 2011). As greater emphasis is placed
on prevention of chronic diseases, indicated by the recent press
release of the International Agency for Research on Cancer to coin-
cide with World Cancer Day (WHO, 2014), more people may begin
seeking nutraceuticals (including probiotics) to support their
health. The statement made by Hippocrates, ‘‘Let food be your
medicine and medicine be your food’’ (Sparks, 2006) harmonises
with the current perspective: classical views on dietetics have
persisted to the modern day.
Today Lingzhi is consumed as a nutraceutical (in the form of a
soup/tea or other concoctions) by predominantly Asian pop-
ulations as a means of improving well-being and health. This prac-
tice may have its roots in the Shen Nong Ben Cao Jing, known in the
West as ‘‘The Divine Farmer’s Materia Medica’’, a highly regarded
pharmacopoeia text dating back to the Qin dynasty (221–206
BCE) (Yang, 1998). In this text, six types of ‘‘zhi’’ (characteristics/
qualities) are described, the qing, chi, huang, bai, hei and zi zhi.
All are described as being able ‘‘to prevent senility, prolong life
as to make one immortal’’ (Yang, 1998). Differences in usage varied
between each type, for example, the ‘‘bai zhi’’ (white Ganoderma)
was purported to boost the lung qi (energy), whereas ‘‘hei zhi’’
(black Ganoderma) boosted kidney qi and sharpened hearing
(Yang, 1998). With these descriptions, it is evident why Lingzhi
has been considered a fungus of special capability, a ‘‘plant of
immortality’’ (Stuart, 1911). However, it is also thought that the
reputation of Lingzhi may have arisen by virtue of its rarity and
its use by privileged members of Chinese society, rather than solely
due to anecdotal evidence (Wachtel-Galor et al., 2011).
To set the historical context of using Lingzhi to treat diseases, it
is worth considering that over the past 2000 years, the role of
Lingzhi has been depicted in Chinese literature and art. Several
hundreds of years after the original descriptions of Lingzhi in the
Shen Nong Ben Cao Jing, the poet Jiang Yan (444–505) wrote about
the character for Lingzhi as to ‘‘indicate the speaker’s proper vir-
tue’’, attributing the overarching respect for this fungus to other
poets of his time (Williams, 2007). Nearly a millennium thereafter,
the silversmith Zhu Bishan (c. 1300) crafted his earliest known
work, a Lingzhi shaped drinking cup (no longer extant) (Wilson,
1994). With the progress of another ﬁve centuries, Lingzhi was
portrayed in the art of the Jiajing period (1522–1566) (Wan,
2007). A cover box displayed at the Palace Museum in Beijing
depicts Lingzhi with vapours emanating to form auspicious
Chinese characters, linking with the belief that Lingzhi could confer
immortality, pursued by the Jiajing emperor who incessantly
consumed Lingzhi preparations (Wan, 2007). With a background
spanning more than two millennia, steeped in the culture of the
Chinese people, Lingzhi has found fame and popularity. The
current market for extracts and preparations continues to expand.
However, despite the growing popularity of Lingzhi nutraceuticals,
the question still remains as to whether there is an evidence base
for pharmacological effects of active substances present in the
fungus.
The continued growth in usage of Lingzhi necessitates, amongst
other things, the correct identiﬁcation of species and active ingre-
dients. From a nutraceutical perspective, this also entails the estab-
lishment of safe doses and quality control. These elements have
been considered herein.
3. Taxonomy
Lingzhi has huge economic value predominantly due to its
medicinal and cultural importance. Confusion with respect to
species identiﬁcation could lead not only to complications with
commercial claims, patents and publications, but may also result
in the incorrect treatment of diseases, conﬂicting results with
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mushroom toxicity (Wasser, 2011). For these reasons, it is
important to be unambiguous about which fungus is being referred
to in the literature and when purchasing in the market. These
nomenclatural issues are now extensively covered in this Special
Issue on Ganoderma with an up-to-date revision of the correct
name (Zhou et al., 2015) which should be referred to.
G. lucidum was ﬁrst described by William Curtis in 1781 based
on material grown in England (cited in Wang et al., 2012b). The
ﬁrst scientiﬁc record of G. lucidum from China was made by Teng
in 1934 when he incorrectly identiﬁed a Lingzhi specimen as
G. lucidum (cited in (Wang et al., 2012b)). Further confusion arose
when chlamydospore production was used to distinguish
Ganoderma tsugae from G. lucidum. Like G. tsugae, European
G. lucidum does not produce ovoid chlamydospores in culture,
whereas G. lucidum grown in the USA does (Moncalvo et al., 1995).
Work byHseu (1990) showed thatG. lucidum andG. tsugae repre-
sent two biological species that had recently diverged (Hseu in
(Moncalvo et al., 1995)). Prior to this, Adaskaveg and Glibertson
(1986) reported that North American G. lucidum and European
Ganoderma resinaceum belonged to the same species, yet
Moncalvo et al. (1995) found no evidence of this (Moncalvo et al.,
1995). Ryvarden (1991) (cited in (Moncalvo et al., 1995)) observed
high phenotypic plasticity in Ganoderma and concluded that strong
speciation has not yet been achieved. Variable morphology and
recent divergence is supported by Moncalvo et al. (1995).
Many believe that all taxa can be reliably distinguished using
culture characteristics, where conditions can be tightly controlled,
but that these characteristics are not always useful in deﬁning
monophyletic lineages (Moncalvo et al., 1995). However, culture
characteristics alone may be insufﬁcient to conclusively assign all
specimens to the correct species. Before the advent of modern
molecular biology, there was much taxonomic confusion regarding
certain Ganoderma species (Moncalvo et al., 1995), and even today,
clarity does not prevail. Sequencing data from the internal tran-
scribed spacer (ITS) region of ribosomal DNA, as well as from the
divergent domain D2 region of the large ribosomal subunit gene,
were compared across the Ganoderma genus to the corresponding
positions 425–648 of Saccharomyces cerevisiae, and sequences from
these regions were used to cluster specimens (Moncalvo et al.,
1995). In addition, Cao et al. (2012) used the mitochondrial
small-subunit ribosomal DNA (mt-SSU), DNA-directed RNA
polymerase II subunit (RPB2), and translational elongation factor
1-alpha (TEF1-a) sequences to study the phylogenetic relation-
ships amongst G. tsugae, ‘‘true’’ G. lucidum and ‘‘Lingzhi’’. Cao
et al. (2012), conclude that G. tsugae grown on conifers in north
eastern China is conspeciﬁc with European G. lucidum; that G. luci-
dum and ‘‘Lingzhi’’ are different species; and that there is strong
support for renaming G. tsugae from Japan and Taiwan as ‘‘Lingzhi’’.
In addition, work carried out byWang et al. (2012b) was used to
support the conclusion that Chinese Lingzhi was conspeciﬁc with
Ganoderma sichuanense and was a different species from G. lucidum
found in the UK. That is, the fungus named Ganoderma lucidum in
tropical Asia is actually Ganoderma multipileum (Wang et al.,
2009). Similar to the model proposed by Moncalvo et al. (1995),
these conclusions were drawn based on the analyses of three
sequenced regions, namely ITS (non-functional RNA), intergenic
spacers (i.e. non-transcribed DNA) and RPB2, aswell asmorphologi-
cal evidence (Wang et al., 2012b). However, a consensus has not
been reached regarding renaming of incorrectly named species. In
order to assist with the clariﬁcation of the species, Hawksworth
(2005) proposed that a new name be introduced for the European
‘‘G. lucidum’’ and that the well-known Chinese Lingzhi, maintain
the name G. lucidum, while Cao et al. (2012) have proposed that
the original Eurasian G. lucidum retain its name and that the
phylogenetically distinct Lingzhi, predominantly from East Asia, berenamed Ganoderma lingzhi and referred to as Lingzhi. The latter
appears to have been partially adopted (Fatmawati et al., 2013;
Sun et al., 2014).
In addition to classiﬁcation based on morphological characters
and molecular phylogenetic analyses, chemistry may also be
applied to assist with the delineation of closely related species. It
is well known that G. lucidum is rich in polysaccharides and triter-
penoids, and it is possible that both the polysaccharide and triter-
penoid proﬁles could be used to differentiate between various
Ganoderma species providing clarity with respect to classiﬁcation.
Despite the difﬁculties associated with the separation and
identiﬁcation of Ganoderma polysaccharides, Sun et al. (2014)
recently established an high performance liquid chromatography
(HPLC) based methodology to characterise species within the
genus Ganoderma using polysaccharide ﬁngerprint proﬁling.
Polysaccharide ﬁngerprint proﬁles were used to differentiate
between G. lucidum and Ganoderma sinense, and differences were
also noted between different strains, different growth conditions
and different geographic origins (Sun et al., 2014).
In contrast to Ganoderma polysaccharides, a greater volume of
work has been published on the use of triterpenes, particularly
ganoderic acids (GAs), to differentiate between species. In a study
reported in 1999, Chen et al. (1999) were able to use an analysis of
triterpenoids to differentiate between G. tsugae and G. lucidum.
However, although the three G. tsugae strains tested presented
with similar spectral proﬁles, the three G. lucidum strains tested
had proﬁles that were both very different from those generated
from G. tsugae strains, and from each other. This is consistent with
the molecular phylogenetic data previously mentioned and is sup-
ported by the strength of the various clades of the most parsimo-
nious tree presented by Cao et al. (2012). Chen and Chen (2003)
went on to develop the spectral proﬁles further by purifying and
identifying additional GAs using reversed-phase HPLC and semi-
preparative HPLC. Thereafter, Liu et al. (2011) used a sensitive
and selective liquid chromatography-tandem mass spectrometry
method for the simultaneous determination of ﬁve GAs in
G. lucidum, G. sinense and Ganoderma applanatum fruiting bodies.
Care must be taken when applying and developing chemotaxic
criteria as the type and quantity of the informative compound, for
example triterpenes, can be inﬂuenced by the growth stage at
which the product is harvested, which part of the fungus is
harvested, as well as the growth or environmental conditions
(Liu et al., 2012). Although chemotaxonomy may not be useful to
allow for the deﬁnitive delineation of the Ganoderma species at
this time, it will allow rough separation and perhaps more impor-
tantly, facilitate the quality control of Ganoderma products.
4. Modern uses of G. lucidum and proof of effect
In traditional Chinese medicine (TCM), G. lucidum is purported
to support a vast array of health beneﬁts, and modern studies
involving animal models and molecular-based research techniques
have been used to demonstrate numerous pharmacological effects
supporting these claims (Jong and Birmingham, 1992; Sanodiya
et al., 2009; Wachtel-Galor et al., 2011). More speciﬁcally, G. luci-
dum has been shown to have potential in the treatment of modern
diseases such as cancer, diabetes, and Human Immunodeﬁciency
Virus (HIV) (Sanodiya et al., 2009).
Despite the many reported medicinal properties of G. lucidum,
the mechanisms of action have remained poorly deﬁned. With
improvements in modern research techniques, detailed
investigations into these mechanisms of action in which G. lucidum
can exert the observed health beneﬁts are becoming increasingly
possible. In addition, better separation and puriﬁcation techniques
have allowed for the isolation and identiﬁcation of some of the
active components in G. lucidum. Modern researches have focused
Fig. 2. The core molecular structure of ganoderic acids, a subtype of triterpenes that
contain four cyclic and two linear isoprenes. The different chemical compounds in R
groups (R1–R6) determine ganoderic acid subtype and its biochemical properties
(ﬁgure adapted from (Liu et al., 2012)).
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triterpenes.
4.1. Polysaccharides
In addition to triterpenes, polysaccharides from G. lucidum are
also believed to confer a health beneﬁt. Polysaccharides are long
chain sugar molecules joined together by glycosidic bonds.
Various types of polysaccharides, with molecular weights ranging
from 4  105 to 1  106 Daltons have been identiﬁed in the fruiting
body and mycelia of G. lucidum (Sanodiya et al., 2009). Irrespective
of the molecular weight of the polysaccharides, a number of them
have a positive impact on reducing cancer progression (Sanodiya
et al., 2009).
Structural analysis shows that polysaccharides of G. lucidum are
mostly high molecular weight heteropolymers (Fig. 1) (Chan et al.,
2007). Glucose forms the major component of the sugar molecule
together with xylose, mannose, galactose, and fucose in different
conformations. Different types of polysaccharides from this fungus,
with different branching conformations and solubility, can induce
different immune responses with varying immune potencies
(Chan et al., 2007). In addition to the soluble polysaccharides, G.
lucidum also consists of a matrix of the polysaccharide, chitin,
which is largely indigestible and is partly responsible for the physi-
cal hardness of the mushroom (Upton, 2000). Despite evidence
being presented on the effect of individual triterpenes in in vivo
and in vitro experiments, polysaccharide-rich extracts from this
fungus seem to have undergone limited testing, with no results
presented on the effect of individual heteropolymers. This may
be due to the difﬁculties associated with isolation and detection
of such heteropolymers.
4.1.1. Neurological effects
In addition to triterpenes, the polysaccharides found in G. luci-
dum are also believed to confer a neurological beneﬁt. Although lit-
tle scientiﬁc evidence exists and further work is required to
support this claim, G. lucidum has been used for its analgesic and
muscle relaxing properties since ancient times (Zhang et al.,
2011). On the other hand, Matsuzaki et al. (2013) have demon-
strated that the water extract (which therefore contains polysac-
charides) of G. lucidum exhibits an anti-depressant-like effect and
reduces anxiety-type behaviour in rats, a ﬁnding which is yet to
be replicated in studies involving human subjects.
4.1.2. Immune-modulation
G. lucidum polysaccharides have been demonstrated to modulate
and improve immune function in both human studies and mouse
models (Gao et al., 2003; Wang et al., 2007). Administration ofFig. 1. The molecular structure of polysaccharides from G. lucidum.consist of D-Galactose
et al., 2010)). (For interpretation of the references to colour in this ﬁgure legend, the reG. lucidum extracts resulted in increased secretion of cytokines from
immune cells which leads to increased cellular activity and survival
of immunecells related to innate (macrophages) and adaptive immu-
nity (lymphocytes) (Bach et al., 2009; Mantovani and Sica, 2010).
These polysaccharides have also been found to improve anti-tumour
immune response by promoting the activity of natural killer cells and
cytotoxic T-lymphocytes (Chang, 2004; Pan et al., 2013). In addition,
the polysaccharides from this fungus are shown to enhance
expression of major histocompatibility complex in a melanoma cell
line, which improves antigen presentation thus promoting viral and
cancer immunity (Sun et al., 2011).
4.2. Triterpenes
Triterpenes are one of the main biologically active groups of
compounds that contribute to the various health beneﬁts of
G. lucidum (Shi et al., 2010; Wachtel-Galor et al., 2011).
Triterpenes are a subtype of terpenes composed of six isoprene
units. The isoprenes in triterpenes may form linear chains, or ring-
like structures. GAs are a subtype of triterpenes with four cyclic
and two linear isoprenes (Liu et al., 2012). There are over 140 spe-
cies of GAs that have been identiﬁed from G. lucidum (Yue et al.,
2010). The core molecular structure of GA is shown in Fig. 2. The
various types of GAs are characterised by different R-groups.
Triterpenes are low molecular weight compounds which can
target cellular processes such as apoptosis, cell cycle regulation
and angiogenesis through direct interaction with molecular targets
(Ferreira et al., 2010; Froufe et al., 2013). Results from a number of
studies have been published wherein a speciﬁc triterpene or a mix-
ture of triterpenes, isolated from G. lucidum, have been identiﬁed,
together with an association with various health beneﬁts. These
associations will be discussed in the following subsections.
4.2.1. Anti-oxidative effect
Free radicals and reactive oxygen species (ROS) are generated as
by-products of metabolic processes involving redox enzymes andmonomers. The glycosidic bonds are highlighted in yellow (ﬁgure adapted from (Ye
ader is referred to the web version of this article.)
Fig. 4. Ganoderic acid Me (3) and ganoderic acid T (4) (ﬁgure adapted from Tang
et al., 2006).
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to some exogenous chemicals (Alphay, 2014; Yue et al., 2006). ROS
and free radicals can damage cells through oxidation, and
long-term accumulation of such damage causes aging and various
age-associated diseases (Lobo et al., 2010). Studies have been used
to show that G. lucidum increases the activity of super oxide dismu-
tase and catalase which are enzymes involved in removing harmful
ROS (Ajith et al., 2009; Cherian et al., 2009; Smina et al., 2011). In
addition, administration of triterpenes to mice increased the
activity of antioxidant enzymes, and reduced radiation-induced
oxidative DNA damage in mice splenocytes (Stojkovic et al., 2014).
4.2.2. Anti-cancer and cytotoxic activities
G. lucidum has been shown to have anti-cancer activity in in vivo
(mouse model) and cytotoxic effects in in vitro (cancer cell lines)
studies (Wachtel-Galor et al., 2011). Various types of extracts from
G. lucidum have shown carcinostatic effects in a wide variety of
cancer cell lines, including breast, pancreas, lung, colon, skin, and
prostate (Wachtel-Galor et al., 2011). There are many mechanisms
by which the G. lucidum extracts exhibit anti-cancer activities.
These include direct inhibition of cell proliferation through can-
cer-speciﬁc cell cycle arrest and apoptosis (Fukuzawa et al.,
2008; Jedinak et al., 2011; Tang et al., 2006; Wu et al., 2012). In
addition, a number of researchers have shown that treatment of
cancer cells with G. lucidum extracts can lead to down-regulation
of cell cycle-associated proteins resulting in cell cycle arrest
(Jedinak et al., 2011; Sliva et al., 2012; WHO, 2014; Wu et al.,
2013). Apoptosis of cancer cell lines was also observed after treat-
ment with G. lucidum triterpenes and Fukuzawa et al. (2008) and
Tang et al. (2006) demonstrated that apoptosis is triggered by
the increase of pro-apoptotic proteins and decrease of anti-apop-
totic proteins. In a study by Liu et al. (2012) the structural activity
relationship of GA-DM (Fig. 3) was investigated and it was found to
inhibit the proliferation of the aggressive human prostate cancer
cell line PC3. GA-DM (1) and various analogues were tested for
growth inhibition in PC3 and it was found that the carbonyl group
at C-3 is essential for growth inhibition (Fig. 3) (Liu et al., 2012).
Furthermore, Liu et al. (2012) also found that an analogue of
GA-DM (2), with a methyl group at C-26, can more effectively
penetrate the membrane and is subsequently metabolised to
GA-DM by PC3. In addition to evidence obtained regarding the
cytotoxicity of G. lucidum, Thyagarajan et al. (2010) showed that
a G. lucidum triterpene extract inhibited tumour growth in a mouse
model with xenograft human colon cancer (Thyagarajan et al.,
2010). Subsequently, De Silva et al. (2012) demonstrated that a
triterpene extract of G. lucidum given orally, signiﬁcantly reduced
colon tumour formation and inﬂammation in mice exposed to
carcinogens.
4.2.3. Anti-metastatic activities
Cancer metastasis is a complex process by which cancer cells
dissociate from the primary tumour and invade other tissues
forming secondary tumours (Leber and Efferth, 2009). Cancer
metastasis, when left untreated, dramatically reduces the rate of
cure and survival (Leber and Efferth, 2009). MatrixFig. 3. Ganoderic acid DM (1) and its analogue (2) (ﬁgure adapted from Liu et al.,
2012).Metalloproteinases (MMP) are a family of proteins that degrade
the extracellular matrix and can promote cancer metastasis
(Bielawski et al., 2008; Liu et al., 2012; Shuman Moss et al., 2012).
A number of researchers have shown that GA-Me (3) (Fig. 4)
and -T (4) (Fig. 4) suppressed the invasion of LLC and HCT-116meta-
static cancer cells via inhibition of pre-metastatic gene expression
such as urokinase-type plasminogen activator and MMP-2 and -9
(Chen et al., 2008; Chen and Zhong, 2011; Zong et al., 2003).
4.2.4. Anti-HIV activity
HIV is a highly infectious virus affecting an estimated 35 million
people worldwide (Paydary et al., 2013). HIV induces a lethal and
incurable condition known as acquired immunodeﬁciency syn-
drome (AIDS). Current treatment strategies for HIV involve delay-
ing the progression of the disease into AIDS (Paydary et al.,
2013). Research on the effects of G. lucidum on HIV has identiﬁed
various compounds that exhibit inhibitory effects. For example,
triterpenoids in G. lucidum have been shown to have anti-HIV-1
protease activity (Min et al., 1998). In one of the earliest studies
investigating this topic, El-Mekkawy et al. (1998) assayed thirteen
compounds isolated from G. lucidum. Several of these compounds
showed anti-HIV-1 activity, including GA-A (5) (Fig. 5), which
exhibited inhibitory activity against HIV-1 proteases. Although
triterpenoids appear to be the major class of compounds with
anti-HIV effects, G. lucidum also contains laccases which may inhi-
bit HIV-1 reverse transcriptase (Wang and Ng, 2006). It is clear that
much more research must be performed to ascertain a mechanistic
basis for G. lucidum isolates as anti-HIV agents, including
determination of the structure–activity relationship between
triterpenes from G. lucidum and HIV proteases, amongst others.
4.2.5. Effect on lower urinary tract symptoms in men
Lower urinary tract symptoms are often secondary to benign
prostatic hyperplasia (BPH), the latter found commonly amongst
older men (Liu et al., 2007). In two clinical trials carried out in
Japan by Noguchi et al. (2008a, b) on men with slight or moderate
lower urinary tract symptoms (but no suspicion of prostate can-
cer), a dose of 6 mg from a G. lucidum ethanol extract was deemed
to be safe and effective. In addition, the 6 mg dose of the aforemen-
tioned extract was shown to improve the International ProstateFig. 5. Ganoderic acid A (5) (ﬁgure adapted from (El-Mekkawy et al., 1998)).
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volume appeared to be unaffected (Noguchi et al., 2008b).
Suppression effects of prostatic growth by G. lucidum might be
partly due to its ability to inhibit 5a-reductase, which is
over-expressed in BPH tissues (Liu et al., 2007). The enzyme
5a-reductase converts testosterone to the more potent form
dihydrotestosterone which promotes growth of prostate cells by
stimulating the androgen receptor (Liu et al., 2007).
4.2.6. Neuro-protective effect
G. lucidum is believed to have a neuro-protective effect and this
notion is supported by work carried out by Zhang et al. (2011) and
Zhao et al. (2011), wherein a mixture of triterpenoid compounds in
G. lucidum, including methyl GA-A (6), methyl GA-B (7), GA-S1 (8),
and GA-TQ (9) (Fig. 6), promoted neuronal survival and reduced
fatigue (Zhang et al., 2011; Zhao et al., 2012). In addition, the
potential use of this fungus for the treatment of neurological
diseases has also been examined. It was shown that long-term con-
sumption of G. lucidum can decrease the progression of Alzheimer’s
disease (Lai et al., 2008; Zhou et al., 2012). This observed neuropro-
tective effect is achieved by promotion of neuritogenesis and
reduction of senescence of the neurons (Ling-Sing Seow et al.,
2013).
4.2.7. Biotechnological production of G. lucidum triterpenes
Due to the potential medicinal properties of G. lucidum, there
has been an increase in the commercial demand for this fungus.
Various cultivation methods have been developed to increase yield
of the active compounds in G. lucidum, in particular its triterpenes.
However, artiﬁcial cultivation of G. lucidum is time-consuming
and the level of active compounds within the fungus are difﬁcult
to control (Zhong and Tang, 2004). Submerged fermentation has
been used as an alternate method for the efﬁcient production of
GAs (Xu et al., 2010). By manipulating the fermentation conditions
such as medium components, oxygen supply, and pH, the produc-
tion of GAs in the mycelium can be enhanced. It was found that the
addition of sodium and manganese can lead to a 2.8 and a 2.2-fold
increase in the GA content, respectively (Xu et al., 2013, 2014). The
increased GA production is likely due to the activation of cal-
cineurin signalling pathway induced by calcium/sodium exchange
(Xu et al., 2013; Xu and Zhong, 2012). Furthermore, production of
GAs can be improved by deliberate overexpression of speciﬁc
genes in G. lucidum (Xu et al., 2012). Overexpression of
3-hydroxy-3-methylglutaryl CoA reductase, a key enzyme in GA
synthesis, has led to a 2-fold increase in total GA produced (Xu
et al., 2012). In addition, the level of speciﬁc GAs can be increased
using additional chemical conversion processes to convert the ana-
logue impurities to the desired compound (Wang et al., 2012a).Fig. 6. Chemical structures of methyl ganoderic acid A (6), methyl ganoderic acid B
(7), ganoderic acid S1 (8), and ganoderic acid TQ (9) (ﬁgure adapted from Zhang
et al., 2011).More speciﬁcally, it was found that using hydrolysis and acetyla-
tion, the amount of GA-T (4) can be increased 4-fold by converting
the GA-T analogues to GA-T (4) (Wang et al., 2012a).
The production of G. lucidum through enhanced cultivation
methods is increasing. By developing enhanced growth conditions
wherein the concentration of the biologically active ingredients is
increased may help increase health beneﬁt. Both increased produc-
tion and enhanced beneﬁt may help meet and promote demand for
this fungus and enable further development of products containing
G. lucidum within the nutraceutical industry.5. Applications as nutraceuticals
In order to consider G. lucidum as a nutraceutical, it is important
to ﬁrst verify whether the criteria, outlined in the deﬁnition, have
been met. As previously mentioned, there is little consensus on the
meaning of the term ‘‘nutraceutical’’. However, there are various
criteria that have been proposed including whether the product
is isolated from foods; whether the isolated product be sold in a
medicinal form; and whether the proposed nutraceutical has been
shown to protect against chronic disease or show some physiologi-
cal beneﬁt (Health Canada, 1998). The criterion that it be an isolate
or puriﬁed form, has been fulﬁlled: there are many examples of G.
lucidum products being sold in such forms, for example
‘‘GanoPoly’’, an aqueous polysaccharide fraction isolated with
patented methods (Gao et al., 2005). In Section 4 of this review,
the current status of the evidence base for physiological beneﬁts
that G. lucidum may provide, has been outlined. This supports the
latter criterion of the Health Canada deﬁnition of ‘‘nutraceutical’’,
although this must be validated by experts in each of the countries
for which G. lucidum may be marketed under the ‘‘nutraceutical’’
label. The U.S. Food, Drug, and Cosmetics Act (FD&C Act) does
not recognise the term ‘‘nutraceutical’’. However, the concepts
behind the Health Canada proposal are seen in the deﬁnitions
provided for ‘‘food’’ and ‘‘drug’’ in the FD&C Act (U.S. Food and
Drug Administration, 2010). Although there is some debate as to
whether G. lucidum can be regarded as a food, mostly due to its
ﬁbrous nature (5.9%), it does predominantly consist of water
(90%), carbohydrate (2,8%), fat (0.5%) and protein (0.8%) (Mau
et al., 2001), and thus, like all other foods, consists of
macronutrients.
Lingzhi products may be sold as prescription drugs in some
Asian countries, although internationally most are advertised as
dietary supplements (Lai et al., 2004). With approximately 5000
tons of G. lucidum produced annually (based on a 2002 estimate),
at a valuation of more than $2.5 billion US dollars, the economic
impact of these products is globally signiﬁcant (Lai et al., 2004;
Li et al., 2013). There are a large number of G. lucidum products
available, varying in terms of the part of the fungus processed,
the method of extraction, as well as mode of delivery, whether it
be in the form of tonics, pills or powders (Lai et al., 2004). As an
example, one particular product is marketed as a cardiovascular
care formula, in the form of capsules (Encore, 2014). The list of
beneﬁts the manufacturers lay claim to includes support of ‘‘nor-
mal blood pressure’’, ‘‘healthy condition of our heart and blood
vessels’’, and to ‘‘maintain peripheral circulation’’, amongst others
(Encore, 2014). Another product comes in the form of a mixed tea,
including other medicinal mushrooms, the description noting that
it ‘‘supports the body’s immune system, improves vitality and
promotes digestion’’ (Alphay, 2014). In both cases, labelling of
the product is limited to health beneﬁt claims about structure,
function or wellbeing (Alphay, 2014; Encore, 2014; Lai et al., 2004).
Both pharmaceutical products and nutraceuticals may have
adverse effects and drug interactions as the biologically
active components present in the product may exert effects
Fig. 7. Chemical structures of ganoderic acid H (10), ganoderiol F (11), ganoderic
acid D (12), and ganoderic acid F (13).
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body. In terms of interactions with other drugs, G. lucidum extracts
appear to enhance the sensitivity of epithelial ovarian cancer cells
to cisplatin in vitro (Zhao et al., 2011) for example. Similarly, the
polysaccharide fraction 3 of G. lucidum synergises with cisplatin
and arsenic trioxide to inhibit the proliferation of resistant urothelial
carcinoma cells (Huang et al., 2010). There are plenty of studies that
can be used to elucidate the beneﬁcial drug interactions that
G. lucidummay provide, synergism and additive effects such as those
already described. However, studies on the toxicity and adverse
effects of G. lucidum are, to date, much less common. A 2008
in vitro study showed that Lingzhi extracts have the potential to cause
toxicity when exposed to cells at levels higher than those concentra-
tions required for stimulatory effects, with signiﬁcant reduction in
cell viability observed in some cell lines (Gill and Rieder, 2008).
Lingzhi carries with it a long history of usage for various medici-
nal purposes in TCM. This may inﬂuence its perception as a nutra-
ceutical, as many people believe in the effects claimed by TCM
practitioners. For example, the usage of G. lucidum for its
An-Shen effect (tranquilising) was only recently supported with
evidence from an animal model study (Cui et al., 2012) yet has
been used for centuries for its tranquilising effect. This study
showed that the administration of G. lucidum extract increased
total sleep time and non-rapid eye movement signiﬁcantly in rats,
with a possible mechanism related to TNF-a (Cui et al., 2012). More
evidence of this sort is required to appropriately support TCM
claims about the health beneﬁts of G. lucidum products.
In addition to evidence based health claims, it is also important
to identify the bioavailability of the biologically active components
of G. lucidum after oral administration, and very little has been
published in this area. Although single compounds can mediate a
biological effect, nutraceuticals often act through the synergistic
activity of multiple metabolites. It is important to gain a better
understanding of the bioavailability of the active components in
this mushroom under different conditions so as to ensure robust
study designs and to maximise consumer beneﬁt.
Low bioavailability of TCMs is not uncommon after oral
administration of single compounds (Cheng et al., 2013) and this
creates challenges with respect to identiﬁcation and character-
isation of the biologically active compounds (Adamec et al.,
2009), which are more easily identiﬁed when administered
individually. A number of researchers have developed methods
to aid with assessment of the bioavailability of various GAs, whilst
others have studied factors that may inﬂuence bioavailability
(Adamec et al., 2009; Cheng et al., 2013; Gao et al., 2004; Qi
et al., 2012; Teekachunhatean et al., 2012; Zhang et al., 2009).
The number of commercially available reference standards lim-
its the number of triterpenes that can be readily analysed. For this
reason Qi et al. (2012) developed a liquid chromatography – mass
spectrometry method to identify the most effective triterpenes
found in G. lucidumwith the intention of using these results to sub-
sequently identify samples via HPLC, and thus avoid the need for
reference standards. Prior to this, Adamec et al. (2009) successfully
used Group Speciﬁc Internal Standard Technology (better known
as GSIST) to identify and compare the GA content in different G.
lucidum extracts, as well as the time proﬁles of GAs-A (5) and -H
(10), and ganoderiol F (GF) (11) (Fig. 7) in plasma from rats after
receiving a gastric gavage (Adamec et al., 2009). In an effort to
improve bioavailability, Cheng et al. (2013) assessed the bioavail-
ability of GA-D (12), in lipid nanoparticles and in solution (Cheng
et al., 2013). The time to reach peak plasma concentration was
36 min for the GA-D nanoparticles versus 2hrs for the GA-D (12)
in solution (Cheng et al., 2013). Likewise, the absolute bioavailabil-
ity (bioavailability is commonly abbreviated in formulae as ‘‘F’’) of
the GA-D increased from 0.22 in solution to 0.70 in nanoparticles
(Cheng et al., 2013). Earlier, Zhang et al. (2009) found that theabsolute bioavailability of GF (11) in rats was F = 0.015 after oral
administration following fasting (Zhang et al., 2009). Absolute
bioavailability refers to the bioavailability of the compound
administered orally, relative to the bioavailability of the same com-
pound administered intravenously (Balant, 1991). The bioavailabil-
ity of the latter is assumed to be 100% (Balant, 1991).
Proximity of administration to food consumption is believed to
inﬂuence bioavailability and for this reason Teekachunhatean et al.
(2012) assessed the timing of food consumption on the
pharmacokinetics of GA-A (5) and ganoderic acid F (GA-F) (13)
(Fig. 7) after consumption of a water based extract of G. lucidum
in human males. Consistent with other studies, it was found that
time to peak concentration for both GA-A (5) and GA-F (13) were
approximately 30 min in the fasting state. However, if a meal
was consumed prior to oral dosing with these GAs, then time to
peak concentration increased and peak concentration decreased
such that GA-F (13) concentrations were below the lower limit of
quantiﬁcation (0.50 ng/mL) (Teekachunhatean et al., 2012).
Clearly variation exists amongst the GAs with respect to bioavail-
ability and experiments need to be carefully controlled.
Considering G. lucidum as a nutraceutical, its current position is
that of a product requiring additional research and analysis to
elucidate matters of safety, adverse effects, drug interactions,
bioavailability, support for TCM claims, regional differences,
species differences, as well as the environmental conditions under
which it is grown (wild versus cultivated).6. The future of G. lucidum
Nutraceuticals are a growing health care industry worldwide,
and as the occurrence of chronic diseases and awareness of pre-
ventative strategies increase, so too will demand for nutraceuticals.
More and more people are seeking to solve their own health
related problems by using natural products to prevent or amelio-
rate disease. However, as awareness of the need for evidence based
claims rises, so too will requirements of regulatory bodies and
customers.
Lingzhi, owing to its lengthy history as a medicinal mushroom,
has attained an almost divine status in its usage to promote health.
Despite this, for Lingzhi to reach its economic andmedicinal poten-
tial a number of challenges need to be addressed: clarity regarding
the taxonomy of Lingzhi needs to be provided; further work on the
identiﬁcation of active ingredients should be carried out and this
will enable the active ingredients within nutraceutical products
to be measured; dose ranges need to be established for both the
safe and beneﬁcial dose of active ingredients for each disease type;
K.S. Bishop et al. / Phytochemistry 114 (2015) 56–65 63growth conditions may need to be optimised in order to increase
production, maximise the active ingredients and to ensure purity;
and clinical trials will need to be carried out to provide convincing
evidence of beneﬁt against both chronic and infectious diseases. As
Chaturvedi et al. (2011) suggest, perhaps we are moving towards
an era where ‘‘a nutraceutical a day keeps the doctor away’’.Acknowledgements
Funding from NZ Focus to BK, MPG and LRF is acknowledged.
YX was funded by a Phyllis Paykel Memorial Scholarship, and
KSB and LRF were supported by the Auckland Cancer Society
Research Centre.References
Adamec, J., Jannasch, A., Dudhgaonkar, S., Jedinak, A., Sedlak, M., Sliva, D., 2009.
Development of a new method for improved identiﬁcation and relative
quantiﬁcation of unknown metabolites in complex samples: determination of
a triterpenoid metabolic ﬁngerprint for the in situ characterization of
Ganoderma bioactive compounds. J. Sep. Sci. 32, 4052–4058.
Ajith, T., Janardhanan, K., 2007. Indian medicinal mushrooms as a source of
antioxidant and antitumor agents. J. Clin. Biochem. Nutr. 40, 157–162.
Ajith, T.A., Sudheesh, N.P., Roshny, D., Abishek, G., Janardhanan, K.K., 2009. Effect of
Ganoderma lucidum on the activities of mitochondrial dehydrogenases and
complex I and II of electron transport chain in the brain of aged rats. Exp.
Gerontol. 44, 219–223.
Alphay, 2014. Lingzhi – Royal Blend Herbal Tea. <http://www.alphayglobal.com/
Products/Alphay CafeBlends/LingzhiTea> Accessed 23 January 2014.
Bach, J.P., Deuster, O., Balzer-Geldsetzer, M., Meyer, B., Dodel, R., Bacher, M., 2009.
The role of macrophage inhibitory factor in tumorigenesis and central nervous
system tumors. Cancer 115, 2031–2040.
Balant, L.P., 1991. Is there a need for more precise deﬁnitions of bioavailability? Eur.
J. Clin. Pharmacol. 40, 123–126.
Bielawski, K., Bielawska, A., Slodownik, T., Bolkun-Skomicka, U., Muszyñska, A.,
2008. Proline-linked nitrosoureas as prolidase-convertible prodrugs in human
breast cancer cells. Pharmacol. Rep. 60, 171.
Brower, V., 1998. Nutraceuticals: poised for a healthy slice of the healthcare
market? Nat. Biotechnol. 16, 728–731.
Cao, Y., Wu, S.-H., Dai, Y.-C., 2012. Species clariﬁcation of the prize medicinal
Ganoderma mushroom ‘‘Lingzhi’’. Fungal Divers. 56, 49–62.
Chan, W., Law, H., Lin, Z., Lau, Y., Chan, G., 2007. Response of human dendritic cells
to different immunomodulatory polysaccharides derived from mushroom and
barley. Int. Immunol. 19, 891–899.
Chang, S.T., 2004. Mushrooms cultivation, nutritional value, medicinal effect, and
environmental impact. CRC Press, Boca Raton, Fla, Boca Raton, Fla.
Chaturvedi, S., Sharma, P.K., Garg, V.K., Bansal, M., 2011. Role of nutraceuticals in
health promotion. Int. J. Pharm. Technol. Res. 4, 5.
Chen, D.-H., Shiou, W.-Y., Wang, K.-C., Huang, S.-Y., Shie, Y.-T., Tsai, C.-M., Shie, J.-F.,
Chen, K.-D., 1999. Chemotaxonomy of triterpenoid pattern of HPLC of
Ganoderma lucidum and Ganoderma tsugae. J. Chin. Chem. Soc. 46, 47–51.
Chen, D.H., Chen, K.D., 2003. Determination of ganoderic acids in triterpenoid
constituents of Ganoderma tsugae. J. Food Drug Anal. 11, 195–201.
Chen, N.H., Liu, J.W., Zhong, J.J., 2008. Ganoderic acid Me inhibits tumor invasion
through down-regulating matrix metalloproteinases 2/9 gene expression. J.
Pharmacol. Sci. 108, 212–216.
Chen, N.H., Zhong, J.J., 2011. P53 is important for the anti-invasion of ganoderic acid
T in human carcinoma cells. Phytomedicine 18, 719–725.
Cheng, C.-R., Yang, M., Guan, S.-H., Wu, X.-H., Pang, X.-Y., Wang, Y., Yang, Y., Ding, J.,
Guo, D.-A., 2013. Pharmacokinetics of ganoderic acid D and its main metabolite
by liquid chromatography–tandemmass spectrometry. J. Chromatogr. B 930, 1–
6.
Cherian, E., Sudheesh, N.P., Janardhanan, K.K., Patani, G., 2009. Free-radical
scavenging and mitochondrial antioxidant activities of Reishi-Ganoderma
lucidum (Curt: Fr) P. Karst and Arogyapacha-Trichopus zeylanicus Gaertn
extracts. J. Basic Clin. Physiol. Pharmacol. 20, 289–307.
Cui, X.-Y., Cui, S.-Y., Zhang, J., Wang, Z.-J., Yu, B., Sheng, Z.-F., Zhang, X.-Q., Zhang, Y.-
H., 2012. Extract of Ganoderma lucidum prolongs sleep time in rats.
J. Ethnopharmacol. 139, 796–800.
De Silva, D., Rapior, S., Fons, F., Bahkali, A., Hyde, K., 2012. Medicinal mushrooms in
supportive cancer therapies: an approach to anti-cancer effects and putative
mechanisms of action. Fungal Divers. 55, 1–35.
El-Mekkawy, S., Meselhy, M.R., Nakamura, N., Tezuka, Y., Hattori, M., Kakiuchi, N.,
Shimotohno, K., Kawahata, T., Otake, T., 1998. Anti-HIV-1 and anti-HIV-1-
protease substances from Ganoderma lucidum. Phytochemistry 49, 1651–1657.
Encore, 2014. Products. 2014. <http://www.alpha-group.co.nz> Accessed: 23
January 2014.
FAO/WHO, 2002. Guidelines for the evalutaion of probiotics in food. Report of a
Joint FAO/WHO Working Group on Drafting Guidelines fo the Evalutaion of
Probiotics in Food. Ontario, Canada.Fatmawati, S., Kondo, R., Shimizu, K., 2013. Structure–activity relationships of
lanostane-type triterpenoids from Ganoderma lingzhi as a-glucosidase
inhibitors. Bioorg. Med. Chem. Lett. 23, 5900–5903.
Ferreira, I., Vaz, J., Vasconcelos, M.H., Martins, A., 2010. Compounds from wild
mushrooms with antitumor potential. Anti-Canc. Agents Med. 10, 424–436.
Froufe, H.J.C., Abreu, R.M.V., Ferreira, I.C.F.R., 2013. Virtual screening of low
molecular weight mushrooms compounds as potential Mdm2 inhibitors. J.
Enzyme Inhib. Med. Chem. 28, 569–575.
Fukuzawa, M., Yamaguchi, R., Hide, I., Chen, Z., Hirai, Y., Sugimoto, A., Yasuhara, T.,
Nakata, Y., 2008. Possible involvement of long chain fatty acids in the spores of
Ganoderma lucidum (Reishi Houshi) to its anti-tumor activity. Biol. Pharm. Bull.
31, 1933–1937.
Gao, J.J., Nakamura, N., Min, B.S., Hirakawa, A., Zuo, F., Hattori, M., 2004.
Quantitative determination of bitter principles in specimens of Ganoderma
lucidum using high-performance liquid chromatography and its application to
the evaluation of ganoderma products. Chem. Pharm. Bull. 52, 688–695.
Gao, Y., Zhou, S., Jiang, W., Huang, M., Dai, X., 2003. Effects of ganopoly (a
Ganoderma lucidum polysaccharide extract) on the immune functions in
advanced-stage cancer patients. Immunol. Invest. 32, 201–215.
Gao, Y.G., Chan, H., Tang, E., Xu, W., Yang, A., Huang, H., Lan, M., Li, J., Duan, X., Xu,
W.C., Zhou, S., 2005. Antitumor activity and underlying mechanisms of
Ganopoly, the reﬁned polysaccharides extracted from Ganoderma lucidum, in
mice. Immunol. Invest. 34, 171–198.
Gautam, S.P., 2013. Nutraceuticals: a boom to medical industry. Res. Gate Pharm.
Sci. 2, 1–8.
Gill, S.K., Rieder, M.J., 2008. Toxicity of a traditional Chinese medicine, Ganoderma
lucidum, in children with cancer. Can. J. Clin. Pharmacol. 15, e275–e285.
Gordan, J.D., Chay, W.-Y., Kelley, R.K., Ko, A.H., Choo, S.-P., Venook, A.P., 2011. And
what other medications are you taking? J. Clin. Oncol. 29, e288–e291.
Hawksworth, D.L., 2005. Reﬂections on changing names and related nomenclatural
issues in edible and medicinal mushrooms. Int. J. Med. Mushr. 7, 29–38.
Health Canada, 1998. Policy paper – nutraceuticals/functional foods and health
claims on foods. 2014. Health Canada, Canada. <http://www.hc-sc.gc.ca/fn-an/
label-etiquet/claims-reclam/nutra-funct_foods-nutra-fonct_aliment-eng.php>
Accessed 23 January 2014.
Huang, C.-Y., Chen, J.Y.-F., Wu, J.-E., Pu, Y.-S., Liu, G.-Y., Pan, M.-H., Huang, Y.-T.,
Huang, A.M., Hwang, C.-C., Chung, S.-J., 2010. Ling-Zhi polysaccharides
potentiate cytotoxic effects of anticancer drugs against drug-resistant
urothelial carcinoma cells. J. Agric. Food Chem. 58, 8798–8805.
Jedinak, A., Thyagarajan-Sahu, A., Jiang, J., Sliva, D., 2011. Ganodermanontriol, a
lanostanoid triterpene from Ganoderma lucidum, suppresses growth of colon
cancer cells through ss-catenin signaling. Int. J. Oncol. 38, 761–767.
Jenkin, M., 2014. Could mushrooms be the cure for cancer?, The Guardian, vol. 2
Mar, UK.
Jin, X., Ruiz Beguerie, J., Sze, D.M., Chan, G.C., 2012. Ganoderma lucidum (Reishi
mushroom) for cancer treatment. Cochrane Db. Syst. Rev. 6, CD007731.
Jong, S.C., Birmingham, J.M., 1992. Medicinal beneﬁts of the mushroom Ganoderma.
Adv. Appl. Microbiol. 37, 101–134.
Lai, C.S., Yu, M.S., Yuen, W.H., So, K.F., Zee, S.Y., Chang, R.C., 2008. Antagonizing beta-
amyloid peptide neurotoxicity of the anti-aging fungus Ganoderma lucidum.
Brain Res. 1190, 215–224.
Lai, T., Gao, Y., Zhou, S., 2004. Global marketing of medicinal Ling Zhi mushroom
Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) products and
safety concerns. Int. J. Med. Mushr. 6, 6.
Leber, M.F., Efferth, T., 2009. Molecular principles of cancer invasion and metastasis.
Int. J. Oncol. 34, 881–895.
Leung, P.C., Xue, C., Cheng, Y.C., 2003. A Comprehensive Guide to Chinese Medicine.
World Scientiﬁc Publisher.
Li, J., Zhang, J., Chen, H., Chen, X.Q., Lan, L., Liu, C., 2013. Complete mitochondrial
genome of the medicinal mushroom Ganoderma lucidum. PLoS ONE 8, 1–
11.
Ling-Sing Seow, S., Naidu, M., David, P., Wong, K.H., Sabaratnam, V., 2013.
Potentiation of neuritogenic activity of medicinal mushrooms in rat
pheochromocytoma cells. BMC Complement. Altern. Med. 13, 157.
Liu, J., Kurashiki, K., Fukuta, A., Kaneko, S., Suimi, Y., Shimizu, K., Kondo, R., 2012.
Quantitative determination of the representative triterpenoids in the extracts of
Ganoderma lucidumwith different growth stages using high-performance liquid
chromatography for evaluation of their 5a-reductase inhibitory properties.
Food Chem. 133, 1034–1038.
Liu, J., Shimizu, K., Konishi, F., Noda, K., Kumamoto, S., Kurashiki, K., Kondo, R., 2007.
Anti-androgenic activities of the triterpenoids fraction of Ganoderma lucidum.
Food Chem. 100, 1691–1696.
Liu, Y., Liu, Y., Qiu, F., Di, X., 2011. Sensitive and selective liquid chromatography-
tandem mass spectrometry method for the determination of ﬁve ganoderic
acids in Ganoderma lucidum and its related species. J. Pharm. Biomed. Anal. 54,
717–721.
Lobo, V., Patil, A., Phatak, A., Chandra, N., 2010. Free radicals, antioxidants and
functional foods: impact on human health. Pharmacogn. Rev. 4, 118–126.
Mantovani, A., Sica, A., 2010. Macrophages, innate immunity and cancer: balance,
tolerance, and diversity. Curr. Opin. Immunol. 22, 231–237.
Matsuzaki, H., Shimizu, Y., Iwata, N., Kamiuchi, S., Suzuki, F., Iizuka, H., Hibino, Y.,
Okazaki, M., 2013. Antidepressant-like effects of a water-soluble extract from
the culture medium of Ganoderma lucidum mycelia in rats. BMC Complement.
Altern. Med. 13, 370.
Mau, J.-L., Lin, H.-C., Chen, C.-C., 2001. Non-volatile components of several
medicinal mushrooms. Food Res. Int. 34, 521–526.
64 K.S. Bishop et al. / Phytochemistry 114 (2015) 56–65Min, B.S., Nakamura, N., Miyashiro, H., Bae, K.W., Hattori, M., 1998. Triterpenes from
the spores of Ganoderma lucidum and their inhibitory activity against HIV-1
protease. Chem. Pharm. Bull. 46, 1607–1612.
Moncalvo, J.-M., Wang, H.-F., Hseu, R.-S., 1995. Gene phylogeny of the Ganoderma
lucidum complex based on ribosomal DNA sequences. Comparison with
traditional taxonomic characters. Mycol. Res. 99, 1489–1499.
Noguchi, M., Kakuma, T., Tomiyasu, K., Kurita, Y., Kukihara, H., Konishi, F.,
Kumamoto, S., Shimizu, K., Kondo, R., Matsuoka, K., 2008a. Effect of an extract
of Ganoderma lucidum in men with lower urinary tract symptoms: a double-
blind, placebo-controlled randomized and dose-ranging study. Asian J. Androl.
10, 651–658.
Noguchi, M., Kakuma, T., Tomiyasu, K., Yamada, A., Itoh, K., Konishi, F., Kumamoto,
S., Shimizu, K., Kondo, R., Matsuoka, K., 2008b. Randomized clinical trial of an
ethanol extract of Ganoderma lucidum in men with lower urinary tract
symptoms. Asian J. Androl. 10, 777–785.
Pan, K., Jiang, Q., Liu, G., Miao, X., Zhong, D., 2013. Optimization extraction of
Ganoderma lucidum polysaccharides and its immunity and antioxidant
activities. Int. J. Biol. Macromol. 55, 301–306.
Papadopoulos, I., Guo, F., Lees, S., Ridge, M., 2007. An exploration of the meanings
and experiences of cancer of Chinese people living and working in London. Eur.
J. Cancer Care 16, 424–432.
Paterson, R.R., 2006. Ganoderma – a therapeutic fungal biofactory. Phytochemistry
67, 1985–2001.
Paterson, R.R.M., 2008. Cordyceps – a traditional Chinese medicine and another
fungal therapeutic biofactory? Phytochemistry 69, 1469–1495.
Paydary, K., Khaghani, P., Emamzadeh-Fard, S., Alinaghi, S.A., Baesi, K., 2013. The
emergence of drug resistant HIV variants and novel anti-retroviral therapy.
Asian Pac. J. Trop. Biomed. 3, 515–522.
Qi, Y., Zhao, L., Sun, H.H., 2012. Development of a rapid and conﬁrmatory method to
identify ganoderic acids in Ganoderma mushrooms. Front. Pharmacol. 3, 1–7.
Raskin, I., 1992. Salicylate, a new plant hormone. Plant Physiol. 99, 799–803.
Sanodiya, B.S., Thakur, G.S., Baghel, R.K., Prasad, G.B., Bisen, P.S., 2009. Ganoderma
lucidum: a potent pharmacological macrofungus. Curr. Pharm. Biotechnol. 10,
717–742.
Shi, L., Ren, A., Mu, D., Zhao, M., 2010. Current progress in the study on biosynthesis
and regulation of ganoderic acids. Appl. Microbiol. Biotechnol. 88, 1243–1251.
Shiao, M.-S., 2003. Natural products of the medicinal fungus Ganoderma lucidum:
occurrence, biological activities, and pharmacological functions. Chem. Rec. 3,
172–180.
Shuman Moss, L.A., Jensen-Taubman, S., Stetler-Stevenson, W.G., 2012. Matrix
metalloproteinases: changing roles in tumor progression and metastasis. Am. J.
Pathol. 181, 1895–1899.
Sliva, D., 2003. Ganoderma lucidum (Reishi) in cancer treatment. Integr. Cancer Ther.
2, 358–364.
Sliva, D., Loganathan, J., Jiang, J., Jedinak, A., Lamb, J.G., Terry, C., Baldridge, L.A.,
Adamec, J., Sandusky, G.E., Dudhgaonkar, S., 2012. Mushroom Ganoderma
lucidum prevents colitis-associated carcinogenesis in mice. PLoS ONE 7, e47873.
Smina, T.P., De, S., Devasagayam, T.P., Adhikari, S., Janardhanan, K.K., 2011.
Ganoderma lucidum total triterpenes prevent radiation-induced DNA damage
and apoptosis in splenic lymphocytes in vitro. Mutat. Res. 726, 188–194.
Sparks, N.H.C., 2006. The hen’s egg – is its role in human nutrition changing?
World’s Poult. Sci. J. 62, 308–315.
Stojkovic´, D.B., Calhelha, L., Glamocˇlija, R.C., C´iric´, J., van Griensven, A., Sokovic´,
L.J.L.D., Ferreira, I.C.F.R., 2014. A detailed comparative study between chemical
and bioactive properties of Ganoderma lucidum from different origins. Int. J.
Food Sci. Nutr. 65, 42–47.
Stuart, G.A., 1911. Chinese Materia Medica: Vegetable Kingdom. Extensively revised
from F. Porter Smith’sWork by G. A. Stuart. American PresbyterianMission Press.
Sun, L.X., Lin, Z.B., Li, X.J., Li, M., Lu, J., Duan, X.S., Ge, Z.H., Song, Y.X., Xing, E.H., Li,
W.D., 2011. Promoting effects of Ganoderma lucidum polysaccharides on B16F10
cells to activate lymphocytes. Basic Clin. Pharmacol. Toxicol. 108, 149–154.
Sun, X., Wang, H., Han, X., Chen, S., Zhu, S., Dai, J., 2014. Fingerprint analysis of
polysaccharides from different Ganoderma by HPLC combined with
chemometrics methods. Carbohydr. Polym. 114, 432–439.
Tang, W., Liu, J.W., Zhao, W.M., Wei, D.Z., Zhong, J.J., 2006. Ganoderic acid T from
Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung
cancer cells. Life Sci. 80, 205–211.
Teekachunhatean, S.S., Sadja, S., Ampasavate, C., Chiranthanut, N., Rojanasthien, N.,
Sangdee, C., 2012. Pharmacokinetics of ganoderic acids A and F after oral
administration of Ling Zhi preparation in healthy male volunteers. Evid-Based
Compl. Alt. 2012, 780892.
Thyagarajan, A., Jedinak, A., Nguyen, H., Terry, C., Baldridge, L.A., Jiang, J., Sliva, D.,
2010. Triterpenes from Ganoderma lucidum induce autophagy in colon cancer
through the inhibition of p38 mitogen-activated kinase (p38 MAPK). Nutr.
Cancer 62, 630–640.
U.S. Food and Drug Administration, 2010. Title 21 – Food And Drugs. US
Government.
Upton, R., 2000. Reishi Mushroom: Ganoderma lucidum: Standards of Analysis,
Quality Control, and Therapeutics. Am. Herb. Pharmacop.
Wachtel-Galor, S., Yuen, J., Buswell, J.A., Benzie, I.F.F., 2011. Ganoderma lucidum
(Lingzhi or Reishi): A Medicinal Mushroom. Taylor and Francis Group.Wan, M.C.K., 2007. Jiajing emperor and his auspicious words. Arch. Asian Art 57,
95–120.
Wang, D.M., Wu, S.H., Su, C.H., Peng, J.T., Shih, Y.H., Chen, L.C., 2009. Ganoderma
multipileum, the correct name for ‘G. lucidum’ in tropical Asia. Bot. Stud. 50, 451–
458.
Wang, G., Zhao, J., Liu, J., Huang, Y., Zhong, J.J., Tang, W., 2007. Enhancement of IL-2
and IFN-gamma expression and NK cells activity involved in the anti-tumor
effect of ganoderic acid Me in vivo. Int. Immunopharmacol. 7, 864–870.
Wang, H.X., Ng, T.B., 2006. A laccase from the medicinal mushroom Ganoderma
lucidum. Appl. Microbiol. Biotechnol. 72, 508–513.
Wang, J.L., Gu, T., Zhong, J.J., 2012a. Enhanced recovery of antitumor ganoderic acid
T from Ganoderma lucidum mycelia by novel chemical conversion strategy.
Biotechnol. Bioeng. 109, 754–762.
Wang, X.-C., Xi, R.-J., Li, Y., Wang, D.-M., Yao, Y.-J., 2012b. The species identity of the
widely cultivated ganoderma, ‘G. lucidum’ (Ling-zhi), in China. PLoS ONE 7, 1–
12.
Wasser, S., 2011. Current ﬁndings, future trends, and unsolved problems in studies
of medicinal mushrooms. Appl. Microbiol. Biotechnol. 89, 1323–1332.
WHO, 2014. Press Release 224. International Agency for Research on Cancer.
Williams, N.M., 2007. A conversation in poems: Xie Lingyun, Xie Huilian, and Jiang
Yan. J. Am. Orient. Soc. 127, 491–506.
Wilson, J.K., 1994. The Fine Art of Drinking: The Chinese Silversmith Zhu Bishan and
His Sculptural Cups. B. Cleveland Mus. Art 81, 380–401.
Wu, G., Qian, Z., Guo, J., Hu, D., Bao, J., Xie, J., Xu, W., Lu, J., Chen, X., Wang, Y., 2012.
Ganoderma lucidum extract induces G1 cell cycle arrest, and apoptosis in human
breast cancer cells. Am. J. Chin. Med. 40, 631–642.
Wu, G.S., Guo, J.J., Bao, J.L., Li, X.W., Chen, X.P., Lu, J.J., Wang, Y.T., 2013. Anti-cancer
properties of triterpenoids isolated from Ganoderma lucidum – a review. Expert
Opin. Investig. Drugs 22, 981–992.
Xu, J.W., Xu, Y.N., Zhong, J.J., 2012. Enhancement of ganoderic acid accumulation by
overexpression of an N-terminally truncated 3-hydroxy-3-methylglutaryl
coenzyme A reductase gene in the basidiomycete Ganoderma lucidum. Appl.
Environ. Microbiol. 78, 7968–7976.
Xu, J.W., Zhao, W., Zhong, J.J., 2010. Biotechnological production and application of
ganoderic acids. Appl. Microbiol. Biotechnol. 87, 457–466.
Xu, Y.-N., Xia, X.-X., Zhong, J.-J., 2014. Induction of ganoderic acid biosynthesis by
Mn2+ in static liquid cultivation of Ganoderma lucidum. Biotechnol. Bioeng. 111,
2358–2365.
Xu, Y.N., Xia, X.X., Zhong, J.J., 2013. Induced effect of Na(+) on ganoderic acid
biosynthesis in static liquid culture of Ganoderma lucidum via calcineurin signal
transduction. Biotechnol. Bioeng. 110, 1913–1923.
Xu, Y.N., Zhong, J.J., 2012. Impacts of calcium signal transduction on the
fermentation production of antitumor ganoderic acids by medicinal
mushroom Ganoderma lucidum. Biotechnol. Adv. 30, 1301–1308.
Yang, S., 1998. The Divine Farmer’s Materia Medica: A Translation of the Shen Nong
Ben Cao Jing. Blue Poppy Press.
Ye, L., Li, J., Zhang, J., Pan, Y., 2010. NMR characterization for polysaccharide moiety
of a glycopeptide. Fitoterapia 81, 93–96.
Yue, G.F., Tse, K.-P., Leung, G.M.K., Lau, C.B.S., 2006. Comparative studies of various
Ganoderma species and their different parts with regard to their antitumor
and immunomodulating activities in vitro. J. Altern. Complem. Med. 12, 777–
789.
Yue, Q.X., Song, X.Y., Ma, C., Feng, L.X., Guan, S.H., Wu, W.Y., Yang, M., Jiang, B.H., Liu,
X., Cui, Y.J., Guo, D.A., 2010. Effects of triterpenes from Ganoderma lucidum on
protein expression proﬁle of HeLa cells. Phytomedicine 17, 606–613.
Zhang, Q., Zuo, F., Nakamura, N., Ma, C.-M., Hattori, M., 2009. Metabolism and
pharmacokinetics in rats of ganoderiol F, a highly cytotoxic and antitumor
triterpene from Ganoderma lucidum. J. Nat. Med. 63, 304–310.
Zhang, X.Q., Ip, F.C., Zhang, D.M., Chen, L.X., Zhang, W., Li, Y.L., Ip, N.Y., Ye, W.C.,
2011. Triterpenoids with neurotrophic activity from Ganoderma lucidum. Nat.
Prod. Res. 25, 1607–1613.
Zhao, H., Zhang, Q., Zhao, L., Huang, X., Wang, J., Kang, X., 2012. Spore powder of
Ganoderma lucidum improves cancer-related fatigue in breast cancer patients
undergoing endocrine therapy: a pilot clinical trial. Evid. Based Complem.
Altern. Med. 2012, 809614.
Zhao, S., Ye, G., Fu, G., Cheng, J.-X., Yang, B.B., Peng, C., 2011. Ganoderma lucidum
exerts anti-tumor effects on ovarian cancer cells and enhances their sensitivity
to cisplatin. Int. J. Oncol. 38, 1319–1327.
Zhong, J.J., Tang, Y.J., 2004. Submerged cultivation of medicinal mushrooms for
production of valuable bioactive metabolites. Adv. Biochem. Eng. Biotechnol.
87, 25–59.
Zhou, L.-W., Cao, Y., Wub, S.-H., Vlasák, J., Li, D.-W., Li, M.-J., Dai, Y.-C., 2015.
Global diversity of the Ganoderma lucidum complex (Ganodermataceae,
Polyporales) inferred from morphology and multilocus phylogeny.
Phytochemistry 114, 7–15.
Zhou, Y., Qu, Z.Q., Zeng, Y.S., Lin, Y.K., Li, Y., Chung, P., Wong, R., Hagg, U., 2012.
Neuroprotective effect of preadministration with Ganoderma lucidum spore on
rat hippocampus. Exp. Toxicol. Pathol. 64, 673–680.
Zong, W.X., Li, C., Hatzivassiliou, G., Lindsten, T., Yu, Q.C., Yuan, J., Thompson, C.B.,
2003. Bax and Bak can localize to the endoplasmic reticulum to initiate
apoptosis. J. Cell Biol. 162, 59–69.
K.S. Bishop et al. / Phytochemistry 114 (2015) 56–65 65Karen Bishop obtained her PhD at the University of
Natal, South Africa. The focus of her dissertation was
multidrug resistance inMycobaterium tuberculosis. Since
that time she has worked on drug resistance and vac-
cine design in HIV, and in 2010 joined the Auckland
Cancer Society Research Centre at the University of
Auckland where she started work on prostate cancer
and the interaction between genotype and diet. This
interest has led to various genotyping studies, a dietary
intervention study in men with Prostate cancer as well
as involvement in in vitro studies using extracts of
Lingzhi.Chi Hsiu-Juei (Ben) Kao is a PhD candidate in the
Discipline of Nutrition, Faculty of Medical and Health
Science, University of Auckland, New Zealand. His
Masters of Health Science (2013) thesis was on anti-
cancer activity of Lingzhi/Ganoderma extracts. The focus
of Ben’s PhD is Lingzhi/Ganoderma and its use as an anti-
cancer agent. Ben wishes to connect ancient medicine to
modern day science using molecular tools.Yuanye Xu is a medical student at the University of
Auckland and has recently completed his fourth year of
studies towards his MBChB degree. He worked with the
authors during a Summer studentship held at the
Department of Nutrition at the Faculty of Medical and
Health Sciences at the University of Auckland earlier
this year. He is currently interested in pursuing a career
in oncology.Marcus Glucina is the CEO and Director of NZ FOCUS
based in Hong Kong. NZ Focus is supporting the ongoing
research with supplies of wild Lynzhi and other mate-
rials. A former graduate of Auckland University with a
Bcom/LLB, Marcus and his team are working with a
number of Lynzhi based products in North Asia.Russell Paterson has a BSc Honours in Applied
Microbiology from the University of Strathclyde, UK. His
MSc and PhD were in Chemistry from the University of
Manchester, UK, under the supervision of J. D. Bu´Lock, of
fungal secondary metabolism fame. He undertook a 2.5
year postdoctoral appointment at the Boyce Thompson
Institute at Cornell University, New York, USA. Dr
Paterson worked at the Centre for Industrial Innovation,
Strathclyde University for 2 years before being
employed at the international non-governmental orga-
nization, CABI, UK where he was the Senior Scientist
researching Fungal Natural Products. He was awarded
the IOI Professorial Chair in Plant Pathology at the Universiti Putra Malaysia,
Malaysia in 2008. Currently, he is employed as a researcher at the Centre for
Biological Engineering, University of Minho, Portugal. Russell has worked in many
countries particularly in S. E. Asia and was central to a fungal bioprospecting project
in the Iwokrama rain forest of Guyana. The European Research Council conﬁrmed
that he is appointed as an External Reviewer of Projects (2012, 2013). Editorial roles
have included coordinating editor of Mycopathologia, and he is an editor of Current
Enzyme Inhibition, Journal of Earth Science & Climatic Change, and Current Opinion in
Food Science. He has written numerous papers, books and chapters on aspects of
fungal secondary metabolism. This Special Issue was inspired by his 2006 review of
Ganoderma published in Phytochemistry, which has been cited c. 290 times (Scopus)
and is his highest cited paper: It was the inspiration for this Special Issue on the
topic. He has a total publication list of c. 200.
Lynn Ferguson obtained her D.Phil. from Oxford
University, working on the subject of DNA damage, DNA
repair and mutagenesis in yeast. After her return to New
Zealand, she began working as part of the Auckland
Cancer Society Research Centre, using mutagenicity
testing as a predictor of carcinogenesis, with particular
focus on the New Zealand situation. In 2000, she took on
a 50% role as Head of a new Discipline of Nutrition at
The University of Auckland. In more recent years, she
has considered the interplay between genes and diet in
the development of chronic disease, with particular
focus on Inﬂammatory Bowel Disease, a cancer-prone
condition, and also in prostate cancer. As programme leader for the multi-
disciplinary-multiorganisation Nutrigenomics New Zealand, she has been working
with a range of others to bring nutrigenomics tools and potential to the New
Zealand science scene. She has supervised more than 30 students to the successful
completion of B.tech, MSc or PhD. Her laboratory regularly supervises 2-3 summer
students each year. She is the author or co-author of more than 350 peer reviewed
publications as chapters in books or articles in international journals. Her current
H-index (Google Scholar) is 48, with 9334 citations. She serves on the Editorial
Boards of several major journals.
